82 FR 50135 - Acceptance Review for De Novo Classification Requests; Draft Guidance for Industry and Food and Drug Administration Staff; Availability
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration Federal Register Volume 82, Issue 208 (October 30, 2017)
Food and Drug Administration
Federal Register Volume 82, Issue 208 (October 30, 2017)
| Page Range | 50135-50138 | |
| FR Document | 2017-23500 |
[Federal Register Volume 82, Number 208 (Monday, October 30, 2017)] [Notices] [Pages 50135-50138] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-23500] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2017-D-6069] Acceptance Review for De Novo Classification Requests; Draft Guidance for Industry and Food and Drug Administration Staff; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice of availability. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled ``Acceptance Review for De Novo Classification Requests.'' The purpose of this draft guidance is to explain the procedures and criteria FDA intends to use in assessing whether a request for an evaluation of automatic class III designation (De Novo classification request or De Novo request) meets a minimum threshold of acceptability and should be accepted for substantive review. This draft guidance discusses De Novo acceptance review policies and procedures, ``Refuse to Accept'' principles, and the elements of the De Novo Acceptance Checklist and the Recommended Content Checklist and is being issued to be responsive to an explicit deliverable identified in the Medical Device User Fee Amendments of 2017 (MDUFA IV). This draft guidance is not final nor is it in effect at this time. DATES: Submit either electronic or written comments on the draft guidance by December 29, 2017 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. ADDRESSES: You may submit comments on any guidance at any time as follows: Electronic Submissions Submit electronic comments in the following way:Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ``Written/Paper Submissions'' and ``Instructions''). Written/Paper Submissions Submit written/paper submissions as follows: Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ``Instructions.'' Instructions: All submissions received must include the Docket No. FDA-2017-D-6069 for ``Acceptance Review for De Novo Classification Requests; Draft Guidance for Industry and Food and Drug Administration Staff; Availability.'' Received comments will be placed in the docket and, except for those submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday. Confidential Submissions--To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper [[Page 50136]] submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ``confidential.'' Any information marked as ``confidential'' will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.thefederalregister.org/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ``Search'' box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)). An electronic copy of the guidance document is available for download from the internet. See the SUPPLEMENTARY INFORMATION section for information on electronic access to the guidance. Submit written requests for a single hard copy of the draft guidance document entitled ``Acceptance Review for De Novo Classification Requests'' to the Office of the Center Director, Guidance and Policy Development, Center for Devices and Radiological Health (CDRH), Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5431, Silver Spring, MD 20993- 0002 or the Office of Communication, Outreach, and Development, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 3128, Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to assist that office in processing your request. FOR FURTHER INFORMATION CONTACT: Sergio de del Castillo, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 1538, Silver Spring, MD 20993-0002, 301-796-6419; or Stephen Ripley, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-402-7911. SUPPLEMENTARY INFORMATION: I. Background The automatic class III designation for devices of a new type occurs by operation of law and without any action by FDA, regardless of the level of risk posed by the device. Any device that is of a new type that was not in commercial distribution before May 28, 1976, is automatically classified as, and remains within, class III and requires premarket approval unless and until FDA takes an action to classify or reclassify the device section 513(f)(1) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 360c(f)(1)). We refer to these devices as ``postamendments devices'' because they were not in commercial distribution prior to the date of enactment of the Medical Device Amendments of 1976. FDA may classify a device through the De Novo classification process, which is the pathway authorized under section 513(f)(2) of the FD&C Act. A person may submit a De Novo request after submitting a premarket notification under section 510(k) of the FD&C Act (21 U.S.C. 360(k)) and receiving a not substantially equivalent (NSE) determination (section 513(f)(2)(A)(i) of the FD&C Act). A person may also submit a De Novo request without first submitting a premarket notification under section 510(k), if the person determines that there is no legally marketed device upon which to base a determination of substantial equivalence (section 513(f)(2)(A)(ii) of the FD&C Act). Upon receipt of a De Novo request, FDA is required to classify the device by written order (section 513(f)(2)(A)(iii) of the FD&C Act). The classification will be according to the criteria under section 513(a)(1) of the FD&C Act. Per section 513(f)(2)(B)(i) of the FD&C Act, the classification is the initial classification of the device for the purposes of section 513(f)(1) of the FD&C Act. We believe De Novo classification enhances patients' access to beneficial innovation, in part by reducing regulatory burdens. When FDA classifies a device into class I or II via the De Novo classification process, the device can serve as a predicate for future devices of that type, including for 510(k)s (section 513(f)(2)(B)(i)). As a result, after a De Novo request is granted, other device sponsors do not have to submit a De Novo request or premarket application under section 515 of the FD&C Act (21 U.S.C. 360e)) in order to market a substantially equivalent device (see 21 U.S.C. 360c(i), defining ``substantial equivalence''). Instead, other device sponsors can use the less- burdensome 510(k) process, when applicable, as a pathway to market their device. FDA is issuing this draft guidance to provide clarity regarding the Agency's expectations for information to be submitted in a De Novo request and ensure predictability and consistency for sponsors. Focusing the Agency's review resources on complete De Novo requests will provide a more efficient approach to ensuring that safe and effective medical devices reach patients as quickly as possible. Moreover, with the enactment of MDUFA IV, FDA agreed to issuance of draft (and final) guidance which includes a submission checklist to facilitate a more efficient and timely review process to assist with new performance goals. Acceptance review therefore takes on additional importance in both encouraging quality applications from De Novo requesters and allowing the Agency to appropriately concentrate resources on complete applications. FDA anticipates that the Agency and industry may need a period of time to operationalize the policies within this guidance, when finalized. Therefore, if all criteria necessary to meet a minimum threshold of acceptability for De Novo requests as outlined in this guidance, when finalized, are not included in a De Novo request received by FDA before or up to 60 days after the publication of this guidance, when finalized, CDRH staff does not generally intend to refuse to accept. II. Significance of Guidance This draft guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the current thinking of FDA on ``Acceptance Review for De Novo Classification Requests.'' It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if [[Page 50137]] it satisfies the requirements of the applicable statutes and regulations. This draft guidance is not subject to Executive Order 12866. III. Electronic Access Persons interested in obtaining a copy of the draft guidance may do so by downloading an electronic copy from the internet. A search capability for all Center for Devices and Radiological Health guidance documents is available at https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm. Guidance documents are also available at https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm or https://www.regulations.gov. Persons unable to download an electronic copy of ``Acceptance Review for De Novo Classification Requests'' may send an email request to [email protected] to receive an electronic copy of the document. Please use the document number 16055 to identify the guidance you are requesting. IV. Paperwork Reduction Act of 1995 Under the Paperwork Reduction Act (44 U.S.C. 3501-3502), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c) (2)(A) of the PRA (44 U.S.C. 3506 (c)(2)(A)) requires Federal Agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed revision of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document. With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology. De Novo Classification Process (Evaluation of Automatic Class III Designation) OMB Control Number 0910-0844--Revision To aid in the acceptance review, the guidance recommends that requesters complete and submit with their De Novo request an Acceptance Checklist that identifies the location of supporting information for each acceptance element and a Recommended Content Checklist that identifies the location of supporting information for each recommended content element. Therefore, we request revision of OMB control number 0910-0844, ``De Novo Classification Process (Evaluation of Automatic Class III Designation)'' to include the Acceptance Checklist and the Recommended Content Checklist in the hourly burden estimate for De Novo requests. We previously estimated the average burden per response for a De Novo request under 21 U.S.C. 513(f)(2)(i) to be 100 hours and under 21 U.S.C. 513(f)(2)(ii) to be 180 hours. We estimate that it will take approximately 1 hour to prepare an Acceptance Checklist and 1 hour to prepare a Recommended Content Checklist. Our estimate assumes that each De Novo request will include both checklists. Therefore, we estimate the revised average burden per response for a De Novo request under 21 U.S.C. 513(f)(2)(i) to be 102 hours and under 21 U.S.C. 513(f)(2)(ii) to be 182 hours. The revision results in a 104-hour increase in the total burden estimate. The average burden per response is based on estimates by FDA administrative and technical staff that are familiar with the requirements for submission of a De Novo request (and related materials), have consulted and advised manufacturers on submissions, and have reviewed the documentation submitted. Approved operating and maintenance costs for a De Novo request include printing, shipping, and eCopy costs. We believe any increase of the operating and maintenance cost resulting from the addition of the Acceptance Checklist and Recommended Content Checklist to be de minimis. Therefore, we are not requesting revision of the operating and maintenance cost estimate for OMB control number 0910-0844. Respondents to the information collection are medical device manufacturers seeking to market medical device products through submission of a De Novo classification request under section 513(f)(2) of the FD&C Act. FDA estimates the burden of this collection of information as follows: Table 1--Estimated Annual Reporting Burden \1\ -------------------------------------------------------------------------------------------------------------------------------------------------------- Total Number of Number of Total annual Average burden operating and Activity respondents responses per responses per response Total hours maintenance respondent costs \2\ -------------------------------------------------------------------------------------------------------------------------------------------------------- De Novo Request Under 21 U.S.C. 513(f)(2)(i) -------------------------------------------------------------------------------------------------------------------------------------------------------- CDRH................................................... 25 1 25 102 2,550 ............... CBER................................................... 1 1 1 102 102 ............... -------------------------------------------------------------------------------------------------------------------------------------------------------- De Novo Request Under 21 U.S.C. 513(f)(2)(ii) -------------------------------------------------------------------------------------------------------------------------------------------------------- CDRH................................................... 25 1 25 182 4,550 ............... CBER................................................... 1 1 1 182 182 ............... ------------------------------------------------------------------------------------------------ Total De Novo requests............................. .............. .............. 52 .............. 7,384 $6,308 Request for withdrawal\2\.............................. 5 1 5 10 50 $5 ------------------------------------------------------------------------------------------------ [[Page 50138]] Total.......................................... .............. .............. .............. .............. 7,434 $6,313 -------------------------------------------------------------------------------------------------------------------------------------------------------- \1\ There are no capital costs associated with this collection of information. \2\ No change from approved information collection. This information is retained for the convenience of the reader. Dated: October 24, 2017. Anna K. Abram, Deputy Commissioner for Policy, Planning, Legislation, and Analysis. [FR Doc. 2017-23500 Filed 10-27-17; 8:45 am] BILLING CODE 4164-01-P
![Federal Register / Vol. 82, No. 208 / Monday, October 30, 2017 / Notices 50135
patient or unique to that patient’s at https://www.fda.gov/MedicalDevices/ ADDRESSES: You may submit comments
treatment or diagnosis that has been DeviceRegulationandGuidance/ on any guidance at any time as follows:
recorded, stored, processed, retrieved, GuidanceDocuments/default.htm.
Electronic Submissions
and/or derived from a legally marketed Guidance documents are also available
medical device. This information may at https://www.regulations.gov. Persons Submit electronic comments in the
include, but is not limited to, recorded unable to download an electronic copy following way:
patient data, device usage/output of ‘‘Manufacturers Sharing Patient- • Federal eRulemaking Portal:
statistics, health care provider inputs, Specific Information from Medical https://www.regulations.gov. Follow the
incidence of alarms, and/or records of Devices with Patients Upon Request’’ instructions for submitting comments.
device malfunctions or failures. may send an email request to CDRH- Comments submitted electronically,
FDA developed this guidance to Guidance@fda.hhs.gov to receive an including attachments, to https://
convey FDA’s position regarding electronic copy of the document. Please www.regulations.gov will be posted to
manufacturers appropriately and use the document number 1500067 to the docket unchanged. Because your
responsibly sharing patient-specific identify the guidance you are comment will be made public, you are
information with that patient at that requesting. solely responsible for ensuring that your
patient’s request. In general, comment does not include any
Dated: October 24, 2017.
manufacturers may do so without confidential information that you or a
undergoing additional premarket review Lauren Silvis, third party may not wish to be posted,
in advance. FDA generally would not Chief of Staff. such as medical information, your or
consider patient-specific information to [FR Doc. 2017–23517 Filed 10–27–17; 8:45 am] anyone else’s Social Security number, or
be ‘‘labeling,’’ as defined in section BILLING CODE 4164–01–P confidential business information, such
201(m) of the Federal Food, Drug, and as a manufacturing process. Please note
Cosmetic Act (the FD&C Act) (21 U.S.C. that if you include your name, contact
321(m)). FDA is aware that when DEPARTMENT OF HEALTH AND information, or other information that
manufacturers share patient-specific HUMAN SERVICES identifies you in the body of your
information with patients, comments, that information will be
manufacturers also may provide them Food and Drug Administration posted on https://www.regulations.gov.
with supplemental information or other [Docket No. FDA–2017–D–6069] • If you want to submit a comment
materials (e.g., descriptions of intended with confidential information that you
use, benefit and risk information, Acceptance Review for De Novo do not wish to be made available to the
instructions for use) that may be Classification Requests; Draft public, submit the comment as a
considered labeling. Any labeling is Guidance for Industry and Food and written/paper submission and in the
subject to applicable requirements in Drug Administration Staff; Availability manner detailed (see ‘‘Written/Paper
the FD&C Act and FDA regulations. Submissions’’ and ‘‘Instructions’’).
AGENCY: Food and Drug Administration,
In the Federal Register of June 10,
HHS. Written/Paper Submissions
2016 (81 FR 37603), FDA announced the
availability of the draft guidance ACTION: Notice of availability. Submit written/paper submissions as
formerly entitled ‘‘Dissemination of follows:
SUMMARY: The Food and Drug • Mail/Hand delivery/Courier (for
Patient-Specific Information from Administration (FDA or Agency) is
Devices by Device Manufacturers’’ and written/paper submissions): Dockets
announcing the availability of the draft Management Staff (HFA–305), Food and
interested parties were invited to guidance entitled ‘‘Acceptance Review
comment by August 9, 2016. FDA has Drug Administration, 5630 Fishers
for De Novo Classification Requests.’’ Lane, Rm. 1061, Rockville, MD 20852.
considered all of the public comments The purpose of this draft guidance is to
received prior to finalizing this • For written/paper comments
explain the procedures and criteria FDA submitted to the Dockets Management
guidance. intends to use in assessing whether a Staff, FDA will post your comment, as
II. Significance of Guidance request for an evaluation of automatic well as any attachments, except for
This guidance is being issued class III designation (De Novo information submitted, marked and
consistent with FDA’s good guidance classification request or De Novo identified, as confidential, if submitted
practices regulation (21 CFR 10.115). request) meets a minimum threshold of as detailed in ‘‘Instructions.’’
The guidance represents the current acceptability and should be accepted for Instructions: All submissions received
thinking of FDA on ‘‘Manufacturers substantive review. This draft guidance must include the Docket No. FDA–
Sharing Patient-Specific Information discusses De Novo acceptance review 2017–D–6069 for ‘‘Acceptance Review
from Medical Devices with Patients policies and procedures, ‘‘Refuse to for De Novo Classification Requests;
Upon Request.’’ It does not establish any Accept’’ principles, and the elements of Draft Guidance for Industry and Food
rights for any person and is not binding the De Novo Acceptance Checklist and and Drug Administration Staff;
on FDA or the public. You can use an the Recommended Content Checklist Availability.’’ Received comments will
alternative approach if it satisfies the and is being issued to be responsive to be placed in the docket and, except for
requirements of the applicable statutes an explicit deliverable identified in the those submitted as ‘‘Confidential
and regulations. This guidance is not Medical Device User Fee Amendments Submissions,’’ publicly viewable at
subject to Executive Order 12866. of 2017 (MDUFA IV). This draft https://www.regulations.gov or at the
guidance is not final nor is it in effect
sradovich on DSK3GMQ082PROD with NOTICES
Dockets Management Staff between 9
III. Electronic Access at this time. a.m. and 4 p.m., Monday through
Persons interested in obtaining a copy DATES: Submit either electronic or Friday.
of the guidance may do so by written comments on the draft guidance • Confidential Submissions—To
downloading an electronic copy from by December 29, 2017 to ensure that the submit a comment with confidential
the internet. A search capability for all Agency considers your comment on this information that you do not wish to be
Center for Devices and Radiological draft guidance before it begins work on made publicly available, submit your
Health guidance documents is available the final version of the guidance. comments only as a written/paper
VerDate Sep<11>2014 17:59 Oct 27, 2017 Jkt 244001 PO 00000 Frm 00020 Fmt 4703 Sfmt 4703 E:\FR\FM\30OCN1.SGM 30OCN1](https://thefederalregister.org/doc/82_FR_50343/page/1.svg)
![50138 Federal Register / Vol. 82, No. 208 / Monday, October 30, 2017 / Notices
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1—Continued
Total
Number of Average
Number of Total annual operating and
Activity responses per burden per Total hours
respondents responses maintenance
respondent response costs 2
Total ......................................... ........................ ........................ ........................ ........................ 7,434 $6,313
1 There are no capital costs associated with this collection of information.
2 No change from approved information collection. This information is retained for the convenience of the reader.
Dated: October 24, 2017. comment does not include any ‘‘THIS DOCUMENT CONTAINS
Anna K. Abram, confidential information that you or a CONFIDENTIAL INFORMATION.’’ The
Deputy Commissioner for Policy, Planning, third party may not wish to be posted, Agency will review this copy, including
Legislation, and Analysis. such as medical information, your or the claimed confidential information, in
[FR Doc. 2017–23500 Filed 10–27–17; 8:45 am] anyone else’s Social Security number, or its consideration of comments. The
BILLING CODE 4164–01–P confidential business information, such second copy, which will have the
as a manufacturing process. Please note claimed confidential information
that if you include your name, contact redacted/blacked out, will be available
DEPARTMENT OF HEALTH AND information, or other information that for public viewing and posted on
HUMAN SERVICES identifies you in the body of your https://www.regulations.gov. Submit
comments, that information will be both copies to Dockets Management
Food and Drug Administration posted on https://www.regulations.gov. Staff. If you do not wish your name and
• If you want to submit a comment contact information to be made publicly
[Docket No. FDA–2016–D–3275] with confidential information that you available, you can provide this
Product Labeling for Certain Ultrasonic do not wish to be made available to the information on the cover sheet and not
Surgical Aspirator Devices; Guidance public, submit the comment as a in the body of your comments and you
for Industry and Food and Drug written/paper submission and in the must identify this information as
Administration Staff; Availability manner detailed (see ‘‘Written/Paper ‘‘confidential.’’ Any information marked
Submissions’’ and ‘‘Instructions’’). as ‘‘confidential’’ will not be disclosed
AGENCY: Food and Drug Administration, Written/Paper Submissions except in accordance with 21 CFR 10.20
HHS. and other applicable disclosure law. For
Submit written/paper submissions as more information about FDA’s posting
ACTION: Notice of availability.
follows:
of comments to public dockets, see 80
SUMMARY: The Food and Drug • Mail/Hand delivery/Courier (for
FR 56469, September 18, 2015, or access
Administration (FDA or Agency) is written/paper submissions): Dockets
Management Staff (HFA–305), Food and the information at: https://www.gpo.gov/
announcing the availability of the fdsys/pkg/FR-2015-09-18/pdf/2015-
guidance entitled ‘‘Product Labeling for Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852. 23389.pdf.
Certain Ultrasonic Surgical Aspirator Docket: For access to the docket to
Devices.’’ FDA is providing a specific • For written/paper comments
submitted to Dockets Management Staff, read background documents or the
labeling recommendation in this electronic and written/paper comments
guidance to promote the safe and FDA will post your comment, as well as
any attachments, except for information received, go to https://
effective use of ultrasonic surgical www.regulations.gov and insert the
aspirator devices. The labeling submitted, marked and identified, as
confidential, if submitted as detailed in docket number, found in brackets in the
recommendation is being made in light heading of this document, into the
‘‘Instructions.’’
of the risk of tissue dissemination and ‘‘Search’’ box and follow the prompts
Instructions: All submissions received
relates to use of these devices in the and/or go to Dockets Management Staff,
must include the Docket No. FDA–
removal of uterine fibroids. 2016–D–3275 for ‘‘Product Labeling for 5630 Fishers Lane, Rm. 1061, Rockville,
DATES: The announcement of the Certain Ultrasonic Surgical Aspirator MD 20852.
guidance is published in the Federal Devices; Guidance for Industry and You may submit comments on any
Register on October 30, 2017. Food and Drug Administration Staff.’’ guidance at any time (see 21 CFR
ADDRESSES: You may submit either Received comments will be placed in 10.115(g)(5)).
electronic or written comments on the docket and, except for those An electronic copy of the guidance
Agency guidances at any time as submitted as ‘‘Confidential document is available for download
follows: Submissions,’’ publicly viewable at from the internet. See the
https://www.regulations.gov or at SUPPLEMENTARY INFORMATION section for
Electronic Submissions information on electronic access to the
Dockets Management Staff between 9
Submit electronic comments in the a.m. and 4 p.m., Monday through guidance. Submit written requests for a
following way: Friday. single hard copy of the guidance
• Federal eRulemaking Portal: • Confidential Submissions—To document entitled ‘‘Product Labeling for
https://www.regulations.gov. Follow the submit a comment with confidential Certain Ultrasonic Surgical Aspirator
sradovich on DSK3GMQ082PROD with NOTICES
instructions for submitting comments. information that you do not wish to be Devices’’ to the Office of the Center
Comments submitted electronically, made publicly available, submit your Director, Guidance and Policy
including attachments, to https:// comments only as a written/paper Development, Center for Devices and
www.regulations.gov will be posted to submission. You should submit two Radiological Health, Food and Drug
the docket unchanged. Because your copies total. One copy will include the Administration, 10903 New Hampshire
comment will be made public, you are information you claim to be confidential Ave., Bldg. 66, Rm. 5431, Silver Spring,
solely responsible for ensuring that your with a heading or cover note that states MD 20993–0002. Send one self-
VerDate Sep<11>2014 17:59 Oct 27, 2017 Jkt 244001 PO 00000 Frm 00023 Fmt 4703 Sfmt 4703 E:\FR\FM\30OCN1.SGM 30OCN1](https://thefederalregister.org/doc/82_FR_50343/page/4.svg)
Document Created: 2017-10-28 00:29:13
Document Modified: 2017-10-28 00:29:13
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice of availability. | |
| Dates | Submit either electronic or written comments on the draft guidance by December 29, 2017 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. | |
| Contact | Sergio de del Castillo, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 1538, Silver Spring, MD 20993-0002, 301-796-6419; or Stephen Ripley, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-402-7911. | |
| FR Citation | 82 FR 50135 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR